Marshall Wace North America L.P. boosted its stake in PerkinElmer, Inc. (NYSE:PKI) by 26.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 14,898 shares of the medical research company’s stock after acquiring an additional 3,145 shares during the period. Marshall Wace North America L.P.’s holdings in PerkinElmer were worth $1,447,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Hudson Valley Investment Advisors Inc. ADV grew its position in PerkinElmer by 0.6% in the 4th quarter. Hudson Valley Investment Advisors Inc. ADV now owns 19,851 shares of the medical research company’s stock valued at $1,928,000 after acquiring an additional 121 shares in the last quarter. Arizona State Retirement System grew its position in PerkinElmer by 0.6% in the 4th quarter. Arizona State Retirement System now owns 20,862 shares of the medical research company’s stock valued at $2,026,000 after acquiring an additional 121 shares in the last quarter. NEXT Financial Group Inc grew its position in PerkinElmer by 75.0% in the 4th quarter. NEXT Financial Group Inc now owns 350 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 150 shares in the last quarter. Advisor Partners LLC grew its position in PerkinElmer by 4.9% in the 4th quarter. Advisor Partners LLC now owns 3,187 shares of the medical research company’s stock valued at $324,000 after acquiring an additional 150 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its position in PerkinElmer by 1.6% in the 4th quarter. Panagora Asset Management Inc. now owns 10,700 shares of the medical research company’s stock valued at $1,039,000 after acquiring an additional 166 shares in the last quarter. Hedge funds and other institutional investors own 96.84% of the company’s stock.
Shares of PerkinElmer stock opened at $75.00 on Thursday. PerkinElmer, Inc. has a one year low of $62.91 and a one year high of $103.00. The company has a market cap of $8.27 billion, a PE ratio of 36.76, a P/E/G ratio of 1.64 and a beta of 1.33. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.33 and a current ratio of 1.80. The business has a 50-day simple moving average of $84.33 and a 200-day simple moving average of $89.37.
PerkinElmer (NYSE:PKI) last announced its quarterly earnings data on Monday, January 27th. The medical research company reported $1.35 EPS for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. The business had revenue of $805.50 million during the quarter, compared to the consensus estimate of $801.14 million. PerkinElmer had a return on equity of 16.80% and a net margin of 7.89%. The business’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 earnings per share. On average, sell-side analysts predict that PerkinElmer, Inc. will post 4.53 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Investors of record on Friday, April 17th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date of this dividend is Thursday, April 16th. PerkinElmer’s dividend payout ratio (DPR) is 6.83%.
A number of equities analysts have recently commented on the company. Citigroup lowered their price objective on PerkinElmer from $100.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, March 20th. TD Securities boosted their price objective on PerkinElmer from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Needham & Company LLC assumed coverage on PerkinElmer in a research report on Friday, January 3rd. They set a “hold” rating and a $79.00 price objective for the company. UBS Group boosted their price objective on PerkinElmer from $92.00 to $100.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Evercore ISI raised PerkinElmer from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $89.00 to $114.00 in a research report on Thursday, January 2nd. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $83.21.
In related news, Director Alexis P. Michas sold 1,777 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $96.23, for a total value of $171,000.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.62% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Read More: What are Closed-End Mutual Funds?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.